Literature DB >> 8813464

Standards and perspectives in the diagnosis and treatment of pancreatic adenocarcinoma.

U Sulkowski1.   

Abstract

Despite certain advances, the overall prognosis for pancreatic carcinoma has remained extremely dismal. Even now, not more than 5% of all patients diagnosed as having pancreatic carcinoma survive 5 years. With this background, the standards and new developments for this entity are discussed.

Entities:  

Mesh:

Year:  1996        PMID: 8813464     DOI: 10.1159/000201390

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  1 in total

1.  The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine.

Authors:  Fang Xie; Mei Huang; Xiansheng Lin; Chenhai Liu; Zhen Liu; Futao Meng; Chao Wang; Qiang Huang
Journal:  Sci Rep       Date:  2018-05-25       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.